Journal Articles

Donald and Barbara Zucker School of Medicine
Academic Works

2015

De novo mutations in congenital heart disease with
neurodevelopmental and other congenital
anomalies
J. Homsy
S. Zaidi
Y. Shen
J. S. Ware
K. E. Samocha
See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Pediatrics Commons
Recommended Citation
Homsy J, Zaidi S, Shen Y, Ware J, Samocha K, Karczewski K, DePalma S, McKean D, Romano-Adesman A, Chung W, . De novo
mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. . 2015 Jan 01; 350(6265):Article
2742 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/2742. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.

Authors

J. Homsy, S. Zaidi, Y. Shen, J. S. Ware, K. E. Samocha, K. J. Karczewski, S. R. DePalma, D. McKean, A.
Romano-Adesman, W. K. Chung, and +31 additional authors

This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/2742

HHS Public Access
Author manuscript
Author Manuscript

Science. Author manuscript; available in PMC 2016 June 02.
Published in final edited form as:
Science. 2015 December 4; 350(6265): 1262–1266. doi:10.1126/science.aac9396.

De novo mutations in Congenital Heart Disease with
Neurodevelopmental and Other Birth Defects

Author Manuscript

Jason Homsy1,2,§, Samir Zaidi3,§, Yufeng Shen4,§, James S. Ware1,5,6,§, Kaitlin E.
Samocha1,7, Konrad J. Karczewski1,7, Steven R. DePalma1,8, David McKean1, Hiroko
Wakimoto1, Josh Gorham1, Sheng Chih Jin3, John Deanfield9, Alessandro Giardini9,
George A. Porter Jr.10, Richard Kim11, Kaya Bilguvar3,12, Francesc Lopez12, Irina
Tikhonova12, Shrikant Mane12, Angela Romano-Adesman13, Hongjian Qi4,14, Badri
Vardarajan15, Lijiang Ma16, Mark Daly1,7, Amy E. Roberts17, Mark W. Russell18, Seema
Mital19, Jane W. Newburger20, J. William Gaynor21, Roger E. Breitbart20, Ivan Iossifov22,
Michael Ronemus22, Stephan J. Sanders23, Jonathan R. Kaltman24, Jonathan G. Seidman1,
Martina Brueckner3,†, Bruce D. Gelb25,†, Elizabeth Goldmuntz26,27,†, Richard P. Lifton3,28,†,*,
Christine E. Seidman1,8,29,†,*, and Wendy K. Chung30,†,*
1Department

of Genetics, Harvard Medical School, Boston, Massachusetts, USA

2Cardiovascular

Research Center, Massachusetts General Hospital, Boston, Massachusetts,

USA
3Department

of Genetics, Yale University School of Medicine, New Haven, Connecticut, USA

Author Manuscript

4Departments

of Systems Biology and Biomedical Informatics, Columbia University Medical
Center, New York, New York, USA

5NIHR

Cardiovascular Biomedical Research Unit at Royal Brompton & Harefield NHS Foundation
and Trust and Imperial College, London, London, UK

6National

Heart & Lung Institute, Imperial College London, London, UK

7Analytical

and Translational Genetics Unit, Massachusetts General Hospital and Harvard
Medical School, Boston Massachusetts, USA

8Howard

Hughes Medical Institute, Harvard University, Boston, Massachusetts, USA

9Department

of Cardiology, University College London and Great Ormond Street Hospital,

London, UK

Author Manuscript

10Department

of Pediatrics, University of Rochester Medical Center, The School of Medicine and
Dentistry, Rochester, New York, USA
11Section

of Cardiothoracic Surgery, University of Southern California Keck School of Medicine,
Los Angeles, California, USA

†

To whom correspondence should be addressed: ; Email: bruce.gelb@mssm.edu, ; Email: goldmuntz@email.chop.edu, ; Email:
martina.brueckner@yale.edu, ; Email: richard.lifton@yale.edu, ; Email: csediman@genetics.med.harvard.edu, or ; Email:
wkc15@cumc.columbia.edu
§These authors contributed equally to this work
*Co-senior authors
Editor correspondence to: cseidman@genetics.med.harvard.edu

Homsy et al.
12Yale

Page 2

Center for Genome Analysis, Yale University, New Haven, Connecticut, USA

Author Manuscript

13Steven

and Alexandra Cohen Children’s Medical Center of New York, New Hyde Park, New
York, USA

14Department

of Applied Physics and Applied Mathematics, Columbia University, New York, New

York, USA
15Department

of Neurology, Columbia University Medical Center, New York, New York, USA

16Department

of Pediatrics, Columbia University Medical Center, New York, New York, USA

17Department

of Cardiology, Children’s Hospital Boston, Boston, Massachusetts, USA

18Division

of Pediatric Cardiology, University of Michigan, Ann Arbor, Michigan, USA

19Department

of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario,

Author Manuscript

Canada
20Department

of Cardiology, Boston Children’s Hospital, Boston, Massachusetts, USA

21Department

of Pediatric Cardiac Surgery, The Children’s Hospital of Philadelphia, Philadelphia,
Pennsylvania, USA
22Cold

Spring Harbor Laboratory, Cold Spring Harbor, New York, USA

23Department

of Psychiatry, University of California San Francisco, San Francisco, California,

USA
24Heart

Development and Structural Diseases Branch, Division of Cardiovascular Sciences,
NHLBI/NIH, Bethesda, Maryland, USA

Author Manuscript

25Mindich

Child Health and Development Institute and Department of Pediatrics, Icahn School of
Medicine at Mount Sinai, New York, New York, USA
26Department

of Pediatrics, The Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pennsylvania, USA
27Division

of Cardiology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

28Howard

Hughes Medical Institute, Yale University, New Haven, Connecticut, USA

29Cardiovascular

Division, Brigham & Women’s Hospital, Harvard University, Boston,
Massachusetts, USA
30Departments

of Pediatrics and Medicine, Columbia University Medical Center, New York, New

York, USA

Author Manuscript

Abstract
Congenital heart disease (CHD) patients have increased prevalence of extra-cardiac congenital
anomalies (CA) and risk of neurodevelopmental disabilities (NDD). Exome sequencing of 1,213
CHD parent-offspring trios identified an excess of protein-damaging de novo mutations, especially
in genes highly expressed in developing heart and brain. These mutations accounted for 20% of
patients with CHD, NDD and CA but only 2% with isolated CHD. Mutations altered genes
involved in morphogenesis, chromatin modification, and transcriptional regulation, including
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multiple mutations in RBFOX2, an mRNA splice regulator. Genes mutated in other cohorts
ascertained for NDD were enriched in CHD cases, particularly those with coexisting NDD. These
findings reveal shared genetic contributions to CHD, NDD, and CA and provide opportunities for
improved prognostic assessment and early therapeutic intervention in CHD patients.

Author Manuscript

Extra-cardiac congenital anomalies (CA, structural or functional anomalies that arise in
utero) occur in approximately 13% of newborns with congenital heart disease (CHD),
including 2% with a genetic syndrome, almost twice the prevalence observed in infants
without CHD (1). Newborns with CHD are also at risk for the emergence of
neurodevelopmental disorders (NDD), including cognitive, motor, social and language
impairments. NDD occurs in 10% of all children with CHD and in 50% with severe CHD
(2). Explanations to account for the high frequency of CA and NDD in CHD patients
include embryonic circulatory deficits and stresses associated with post-natal therapeutic
interventions (3), but these hypotheses remain unproven.
We sequenced exomes in 1,213 CHD trios, (probands and their unaffected parents) enrolled
in the Pediatric Cardiac Genetics Consortium (PCGC) (4) or the Pediatric Heart Network
(PHN) (5) after excluding CHD cases with clinically recognized genetic syndromes.
Analyses included 353 previously reported CHD trios (6). We compared de novo mutations
identified in CHD that occurred in isolation, or accompanied by CA, NDD, or both
(phenotypes in Tables S1 and Database S1). Previously sequenced trios (n=900) from the
Simons Foundation Autism Research Initiative Simplex Collection, each consisting of the
unaffected parents and sibling of a child with autism spectrum disorder, served as control
trios (7–9).

Author Manuscript

CHD and control probands were analyzed for de novo mutations (Databases S2–3). To
evaluate the significance of mutation frequencies, we adapted a recently reported de novo
expectation model (10) to assess mutation rates by variant class (synonymous, loss of
function [LoF; e.g., nonsense, frameshift, canonical splice disruptions], or missense). We
derived gene-based rates of de novo mutation from local sequence context, and adjusted by
per-base coverage separately in case and control cohorts (Databases S4–5). We extended the
model by merging all possible transcripts to obtain transcript-independent probabilities and
by adding rates for deleterious missense variants predicted by the Meta-SVM score (D-Mis)
(11). This yielded an overall mean expected mutation rate of 1.1 de novo variant per
proband.

Author Manuscript

The expected and observed numbers of de novo mutations in each variant class in all CHD
and control subjects (Table 1) were compared using a Poisson distribution. De novo
mutation rates per variant class were accurately predicted in controls, replicating previous
model validations (10). However, among all CHD trios, we detected significant enrichment
(i.e., observed divided by expected frequencies) of LoF and D-Mis variants of 1.3
(p=0.0016) and 1.6 (p=1.8×10−10), respectively, across all genes. The combination of LoF
+D-Mis variants (hereafter denoted as “damaging”) was 1.4-fold enriched in CHD cases
compared to expectation, similar to the observed case vs. control comparison (Table S2).
This burden persisted after excluding 353 previously studied CHD trios (Table S3) and was
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found in each CHD category (conotruncal defects, left ventricular outflow tract obstruction
and “other”), except for heterotaxy, which showed no excess (Table S4).
Damaging de novo mutations were markedly increased in CHD cases (enrichment=2.4,
p=5.1×10−24) among 4,420 genes in the top quartile of expression during heart development
(high heart expression, HHE (6)) (Table 1). Conversely, controls had no significant
enrichment in de novo mutations in HHE genes. Neither cases nor controls were enriched in
de novo mutations among genes within the lower three quartiles of developing heart
expression (LHE) (Table 1). From the observed and expected values, we estimated that 58%
of these damaging de novo mutations contributed to CHD.

Author Manuscript

Twenty-one genes had multiple damaging de novo mutations only in cases, an unlikely
chance occurrence (Fig. 1A; median expected 7; p=1.1×10−5 by permutation), suggesting
that these genes are likely to be pathogenic for CHD (Fig. 1B). Indeed, this list includes
seven genes previously implicated in CHD (PTPN11, KMT2D, CHD7, MYH6, JAG1,
NOTCH1, ZEB2). Enrichments were not observed among genes with multiple de novo
synonymous variants in CHD cases or across any variant class among controls (Fig. 1A and
Table S5). A variety of cardiac malformations were associated with mutations in each of
these 21 genes (Fig 1B and Table S6). From simulations based on these data (12), we
estimate that de novo mutations in ~392 HHE genes contribute to CHD pathogenesis (Fig.
S1).
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Within this 21-gene set, PTPN11, KMT2D (MLL2), and RBFOX2, each had significantly
more damaging de novo mutations than expected (Bonferroni corrected threshold for
genome-wide significance = p<9×10−7; Fig. 1B). RBFOX2, an RNA binding protein that
regulates alternative splicing has not been previously implicated in CHD. RBFOX2 harbored
three distinct de novo LoF mutations, a highly significant finding (Fig. 1B; p=3.4×10−8).
Additionally, we previously identified a de novo copy number loss that encompasses
RBFOX2 in another CHD proband (13). Remarkably, these four probands all have
hypoplastic left heart syndrome (HLHS). RBFOX2 is critical for zebrafish heart
development (14), and regulates epithelial-mesenchymal transitions (EMT) (15). Disruption
of EMT is felt to underlie HLHS pathogenesis (16). Notably, we observed significant
enrichment of damaging mutations in RBFOX2 target genes (17) in CHD cases (1.9-fold,
p=6.6×10−8) but not controls (Table S7).
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Gene ontology (GO) analysis revealed enrichment of damaging de novo mutations in genes
involved in anatomic structure morphogenesis (GO:0009653; 2.4-fold; Bonferroni
p=3.4×10−14), cardiovascular system development (GO:0072358; 3.2-fold; Bonferroni
p=7.5×10−9), neurodevelopmental abnormality (HP:0012759; 2.6-fold; Bonferroni
p=1.8×10−6), and others (Database S6). We replicated the reported excess of de novo LoF
mutations affecting chromatin modification (6), even after including only newly studied
cases (GO:0016568, 5.1-fold enrichment, p-value=7.2×10−5; Database S7). In the full CHD
cohort, there were 25 de novo LoF mutations in chromatin modifying genes, a 5.3-fold
enrichment over expectation (p=5.7×10−11, Table S8; Fig. S2), strongly supporting the
conclusion that these damaging de novo mutations impart large effects on CHD risk.
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We examined the prevalence of damaging de novo mutations in CHD with or without NDD
and/or CA (Fig 2A–C) after excluding 19 subjects found to have de novo mutations in
known syndromic CHD genes and 279 subjects with uncertain NDD/CA status. Damaging
de novo mutations in HHE genes were not significantly enriched in 356 subjects with
isolated CHD nor in controls, but were ~3-fold enriched in 559 CHD cases with CA and/or
NDD (CHD + Extra, p=1.1×10−18) including 97 probands diagnosed with either NDD or
CA but unknown for the other phenotype. Excluding these 97 probands, we observed a 4.7fold enrichment of damaging de novo mutations in HHE genes among 138 CHD cases with
both NDD and CA (p=5.6×10−15), a 2-fold enrichment in CHD cases with only NDD (252
probands, p=3.8×10−4) and a 2.9-fold enrichment in CHD cases with only CA (72 probands,
p=7.4×10−4). By comparing de novo rates in cases against expectation, we estimate that
damaging de novo mutations in HHE genes contributed to 20% of CHD with both NDD and
CA (95% confidence interval 12–30%), 10% (7–14%) of CHD with CA and/or NDD, 10%
(2.5–23%) and 6% (2–11%) of CHD with CA or NDD only, respectively, and only 2% (0.5–
5%) of isolated CHD (Fig. 2B). These results implied frequent pleiotropic effects of de novo
mutations in CHD and raise the possibility that mutations in these same genes might also
contribute to non-syndromic NDD and/or other CA. Indeed, we find that genes mutated in
CHD are not only enriched for high expression in developing heart, they are also enriched
for high expression in developing brain (Table S9).
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To further explore these pleiotropic effects, we considered whether genes with damaging de
novo mutations in CHD with NDD overlapped with 1,161 genes (Database S8) found to
contain damaging de novo mutations in seven cohorts ascertained for NDD phenotypes
excluding CHD (published NDD, P-NDD gene set) (7, 18–23). Sixty-nine genes (Table S10)
with damaging de novo mutations (n=85 mutations) were shared in CHD and P-NDD
cohorts, far more than expected by chance (expected = 32 mutations; 2.6-fold enrichment;
p=8.9×10−15, Fig. 3A and Table S19). HHE genes were particularly enriched among P-NDD
genes that were mutated in CHD (4.4-fold for all CHD cases, p=1.2×10−23; Fig. 3A and
Table S11). Moreover, genes mutated both in P-NDD and CHD cohorts are in the top
quartile of both developmental heart and brain expression far more than expected by chance
(observed = 38, expected = 11, p=6.1×10−11, binomial test, Fig. 3B). Input of these 69
overlapping genes into GO ontology analysis revealed significant terms that were broadly
involved in the regulation of developmental transcription programs. These included 19
chromatin modifiers (GO:0016568 9.3-fold, p=8.5×10−10; Database S9 and Fig. S2)
including genes responsible for altering the methylation, acetylation or ubiquitination status
of numerous regulatory lysine residues on the nucleosome. Additionally, there were 32
transcriptional regulators (GO:0006355 2.8-fold p=1.5×10−4; Database S9), including genes
involved in the Wnt (CTNNB1, DVL3, LRP5) and Notch (NOTCH1, EP300) signaling,
important pathways in cardiac development. These findings demonstrate shared genetic
etiologies for CHD and NDD patients, and confirm pleiotropic effects of mutations in these
genes. Because it is unlikely that many P-NDD-ascertained patients with these mutations
had clinically important CHD, and not all CHD patients with these mutations have NDD
(see below), our findings also indicate that these mutations have variable expressivity,
including isolated CHD, isolated NDD, or both.
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Consistent with these observations, CHD subjects with damaging de novo mutations in these
69 overlapping genes (Fig. 3A) had a significantly increased risk of NDD (absolute risk of
73%, odds ratio 3.1, p=7.9×10−5, Fisher exact test). Damaging mutations (28 mutations in
27 subjects) in chromatin modifiers showed the highest risk of NDD (19 subjects with NDD,
8 with unknown NDD status due to age <1 year at evaluation). Moreover, the marked
enrichments in damaging de novo mutations among P-NDD genes with HHE (Fig. 3A and
Table S11), 7.4-fold in 413 CHD cases with NDD (p=3.9×10−22), 4.1-fold in 362 CHD
infants with unknown NDD status (p=2.2×10−7) and no significant enrichment in 438 CHD
cases without NDD (p=0.075), strongly implies a future risk of NDD among CHD infants
with these variants. These observations suggest that genotype is a strong predictor for future
development of NDD in CHD infants. Despite these highly significant findings, our
estimates are based purely on statistical grounds and limited to in silico predictions of
damaging variants, a caveat that should be considered when extrapolating these results to
identify causative/predictive mutations in individual patients.

Author Manuscript

Contemporary therapeutic interventions have substantially improved survival among
newborns with serious CHD. Despite these advances, many life-long medical issues remain.
The demonstration that damaging de novo gene mutations cause CHD, particularly when
associate with NDD and other birth defects has both clinical and research implications. First,
clinical genotyping may help stratify CHD patients and identify those at high risk for NDD,
enabling surveillance and early interventions to improve school performance, employability
and quality of life. Second, the pleiotropic consequence of these mutations implies that
further study of these genes may uncover critical regulation of broad developmental
programs. Finally, the high frequency of mutation in transcriptional regulators suggests that
mutations in regulatory elements (promoters and enhancers) may be additional causes of
CHD, particularly isolated CHD.
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Fig. 1.
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Genes with multiple de novo mutations are candidate CHD risk genes. A: Histograms show
the expected distribution of the number of genes containing multiple de novo mutations
(empirically derived using 1M permutations, black), and the observed number of genes with
multiple mutations in cases (red line) for each class. P-values were calculated by
permutation. B: Twenty-one genes with multiple damaging de novo mutations in cases. Pvalues are from Poisson test against expectation, with significance threshold < 9×10−7.
Further details are shown in Table S6.
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Fig. 2.

Burden of damaging de novo mutations in HHE genes among CHD cases with extra-cardiac
phenotypes. A: The enrichment (ratio of observed/expected) of damaging de novo mutations
in HHE genes is shown for each phenotype (± 95% confidence interval). Case probands
were excluded if they carried de novo mutations in known CHD syndrome genes (n=19),
had unknown extracardiac phenotype for both NDD and CA (n=6), or had one unknown
phenotype and were negative for the other (n=273). Cases with either CA or NDD and
unknown status for the other phenotype (n=97) were included in the “Extra” category but
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excluded from the “only” categories. B: Percent excess of individuals carrying damaging de
novo mutations in HHE genes by indicated phenotype (± 95% confidence interval).
Explanation of calculation is provided (12). C: Table of observed and expected de novo rates
for the indicated variant classes by phenotype.
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Fig. 3.
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Genes containing de novo mutations in CHD cases show pleotropic developmental effects.
A: Individuals with CHD carry an excess of damaging de novo mutations among 1,161
genes identified by containing damaging de novo mutations in 7 published studies of NDD
(P-NDD cohort) (7, 18–23). All CHD cases were subdivided by NDD status (CHD + NDD,
n=417 subjects, CHD – NDD n=440, Unknown NDD, n=363). P-values ≤ 0.005 as indicated
(stars) were calculated from Poisson test against model-derived distribution (values in Table
S11). P-NDD gene set (blue) was further filtered for HHE genes (P-NDD/HHE, red, 564
genes). Enrichments are shown ± 95% confidence intervals. B: Percentile gene expression
ranks (100=high) are shown for all genes (grey) in the developing brain and heart,
highlighting 69 genes with damaging de novo mutations in both CHD cases and the P-NDD
cohort (blue or purple). Genes with multiple de novo mutations in CHD (red or purple) are
shown. Point size represents numbers of de novo events.
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